Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

FDMT
4D Molecular Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Aug 29, 2025 3:59:57 PM EDT
6.16USD-0.324%(-0.02)342,592
0.00Bid   0.00Ask   0.00Spread
Pre-market
Aug 28, 2025 8:36:30 AM EDT
6.56USD+6.149%(+0.38)0
After-hours
Aug 29, 2025 4:00:30 PM EDT
6.16USD0.000%(0.00)47,852
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
08:06AM EST  4D Molecular Therapeutics Reports FDA Fast Track Designation For Its 4D-125 For Treatment Of X-Linked Retinitis Pigmentosa   Benzinga
08:02AM EST  4D Molecular Therapeutics Announces FDA Fast Track Designation   GlobeNewswire Inc
Jan 7, 2022
01:03PM EST  The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs   Benzinga
Jan 6, 2022
04:03PM EST  4D Molecular Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Of 4D-150, A Dual-Transgene Intravitreal Gene Therapy For Patients With Wet AMD   Benzinga
04:03PM EST  4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-150 for neovascular age-related macular degeneration (wet AMD).   GlobeNewswire Inc
Jan 4, 2022
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2022   Benzinga
06:05AM EST  SVB Leerink Initiates Coverage On 4D Molecular Therapeutics with Outperform Rating, Announces Price Target of $30   Benzinga
Nov 29, 2021
04:00PM EST  Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of   GlobeNewswire Inc
Nov 23, 2021
04:05PM EST  4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in a fireside chat at the Evercore ISI HealthCONx 2021 Conference. The fireside chat will take place on Thursday, December 2nd, 2021 at 10:55 a.m. ET.   GlobeNewswire Inc
Nov 10, 2021
05:01PM EST  4D Molecular Therapeutics Q3 EPS $(0.82) Up From $(1.51) YoY, Sales $1.37M Down From $7.42M YoY   Benzinga
04:01PM EST  4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the third quarter of 2021 and provided operational highlights.   GlobeNewswire Inc
Oct 29, 2021
02:38PM EDT  Mid-Afternoon Market Update: Gold Down 1%; A10 Networks Shares Gain Following Q3 Results   Benzinga
02:01PM EDT  Shares of 4D Molecular Therapeutics Inc. (FDMT) are slipping over 22% after the clinical-stage gene therapy company said it priced a secondary offering of 4.75 million shares at $25.00.   RTTNews
08:00AM EDT  The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs   Benzinga
Oct 26, 2021
05:58PM EDT  4D Molecular Therapeutics Announces Proposed Public Offering Of 4.5M Shares Of Common Stock   Benzinga
08:36AM EDT  The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children   Benzinga
08:28AM EDT  4D Molecular's Fabry Disease Candidate Shows Early Proof-Of-Concept   Benzinga
Oct 25, 2021
04:04PM EDT  4D Molecular Therapeutics Reports Interim Results From Phase 1/2 Trial Of Its Fabry Disease Candidate: 'AGA enzyme activity was within, or significantly above, the normal range in all three patients'   Benzinga
04:03PM EDT  - First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution   GlobeNewswire Inc
Oct 11, 2021
10:24AM EDT  4D Molecular Therapeutics Early Sunday Highlighted Presentation Of Interim Results From Ongoing 4D-125 Phase 1/2 Trial In Patients With Advanced X-Linked Retinitis Pigmentosa At American Society Of Retina Specialists Meeting   Benzinga
Oct 10, 2021
03:50PM EDT  4D Molecular Therapeutics Presents Interim Results from the   GlobeNewswire Inc
11:59AM EDT  The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage   Benzinga
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
08:05AM EDT  4D Molecular Therapeutics (FDMT) said the FDA has cleared the Investigational New Drug Application for 4D-150 for wet age-related macular degeneration. This enables the initiation of 4D-150 phase 1/2 clinical trial sites, which is expected before year-end.   RTTNews
07:47AM EDT  4D Molecular Therapeutics Announces FDA Clearance Of IND Application For 4D-710 And 4D-150   RTTNews
07:33AM EDT  4D Molecular Therapeutics Announces FDA Clearance Of IND Application For 4D-150, A Dual-Transgene Intravitreal Gene Therapy For Patients With Wet AMD   Benzinga
07:30AM EDT  4D Molecular Therapeutics Announces FDA Clearance of IND   GlobeNewswire Inc
Sep 29, 2021
04:02PM EDT  4D Molecular Therapeutics To Participate In Chardan's 5th Annual Genetic Medicines Conference Oct. 4   Benzinga
04:01PM EDT  4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in Chardans 5th Annual Genetic Medicines Conference being held virtually on Monday, October 4. Details of the fireside chat are as follows:   GlobeNewswire Inc
Sep 24, 2021
07:04AM EDT  4D Molecular Therapeutics Announces Late-Breaking Presentation Of 4D-125 Clinical Data At the Upcoming ASRS Annual Meeting Oct. 10   Benzinga
07:03AM EDT  4D Molecular Therapeutics Announces Late-Breaking Presentation of   GlobeNewswire Inc
Aug 12, 2021
04:46PM EDT  4D Molecular Therapeutics Q2 EPS $(0.28) Up From $(2.92) YoY, Sales $14.58M Up From $3.63M YoY   Benzinga
04:04PM EDT  4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the second quarter of 2021, and provided operational highlights.   GlobeNewswire Inc
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jun 25, 2021
07:32AM EDT  The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs   Benzinga
Jun 24, 2021
11:10AM EDT  Stocks That Hit 52-Week Lows On Thursday   Benzinga
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
07:03AM EDT  4D Molecular Therapeutics Announces Roche's Termination Of Collaboration And License Agreement For 4D-110; 4DMT To Regain Full Rights To 4D-110   Benzinga
07:01AM EDT  4D Molecular Therapeutics Announces Rare Disease Ophthalmology   GlobeNewswire Inc
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 18, 2021
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jun 7, 2021
07:14AM EDT  4D Molecular Therapeutics Appoints Carolyne Zimmermann As Chief Business Officer   RTTNews
07:00AM EDT  4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief   GlobeNewswire Inc
Jun 3, 2021
07:00AM EDT  4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 2:30 p.m. PT.   GlobeNewswire Inc
May 25, 2021
07:53AM EDT  The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
04:14PM EDT  4D Molecular Therapeutics Q1 EPS $(0.61) Up From $(2.54) YoY, Sales $2.00M Down From $3.50M YoY   Benzinga
04:03PM EDT  4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the first quarter of 2021, and provided operational highlights.   GlobeNewswire Inc
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
05:30PM EDT  4D Molecular Therapeutics Presents Non-Human Primate Preclinical   GlobeNewswire Inc
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 4, 2021
04:36PM EDT  4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform   Benzinga
04:02PM EDT  4D Molecular Therapeutics Announces Collaboration on Leading   GlobeNewswire Inc
Apr 30, 2021
07:05AM EDT  4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will present at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13 at 2:00 p.m. PT.   GlobeNewswire Inc
Apr 27, 2021
04:34PM EDT  4D Molecular Therapeutics Announces Preclinical Data Presentations At ASGCT And ATS Annual Meetings On Three Wholly-Owned Product Candidates From Non-Human Primate Studies   Benzinga
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:45AM EDT  Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join   GlobeNewswire Inc
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 19, 2021
10:18AM EDT  Stocks That Hit 52-Week Lows On Monday   Benzinga
Apr 16, 2021
08:01AM EDT  The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Apr 5, 2021
06:59AM EDT  Invitae Shares Are Trading Higher On SoftBank's Potential $1.2B Debt Investment: WSJ   Benzinga
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
Mar 25, 2021
04:03PM EDT  4D Molecular Therapeutics Reports FY20 Sales 13.612M Up From $6.986M YoY   Benzinga
04:02PM EDT  - First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease   GlobeNewswire Inc
Mar 9, 2021
09:17AM EST  4D Molecular Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Of 4D-310 For Treatment Of Fabry Disease   Benzinga
09:17AM EST  4D Molecular Therapeutics Reports First Patient Dosed In Phase 1/2 Trial Of 4D-310 For Treatment Of Fabry Disease   Benzinga
08:03AM EST  4D Molecular Therapeutics Announces First Patient Dosed in Phase   GlobeNewswire Inc
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 6, 2021
07:31AM EST  The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping   Benzinga
Jan 5, 2021
10:11AM EST  Benzinga's Top Upgrades, Downgrades For January 5, 2021   Benzinga
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
07:27AM EST  B of A Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $47   Benzinga
05:12AM EST  Goldman Sachs Initiates Coverage On 4D Molecular Therapeutics with Neutral Rating, Announces Price Target of $44   Benzinga
Dec 15, 2020
04:05PM EST  4D Molecular Therapeutics Announces Closing of Initial Public   GlobeNewswire Inc
Dec 11, 2020
12:09PM EST  4D Molecular Therapeutics Shares Open At $40; IPO Priced At $23   Benzinga
09:46AM EST  IPOs for today: VVOS, ABCL, EDTXU, GLAQU, TVACU, SNRHU, NBTX, ROCCU, GHVIU, CERT, FDMT, MOTVU, DWINU, CBAHU, PCPCU   Benzinga
09:11AM EST  4D Molecular Therapeutics Shares Will Open For Quote At 11 a.m. EST, Expected To Open For Trade After 11:10 a.m. EST: IPO Priced At $23/Share   Benzinga
12:09AM EST  Emeryville, California-based 4D Molecular Therapeutics is scheduled to make its debut on the Nasdaq Global Select Market today (December 11), under the ticker symbol "FDMT."   RTTNews


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC